Adénopathies médiastinales dans la sclérodermie systémique diffuse : une étude observationnelle sur 48 patients

Renaud, A.; Pautre, R.; Morla, O.; Durant, C.; Espitia, O.; Frampas, E.; Agard, C.

doi:10.1016/j.revmed.2021.03.313

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is more severe in men and in patients with concomitant inflammatory myopathy. [8] Clinically, it manifests itself in the form of dysphagia, GERD, telangiectasias on gastric endoscopic imaging, malabsorption syndrome, and variable bowel movements.…”

Section: Symptomsmentioning

confidence: 99%

Advances in the Understanding, Diagnosis, and Treatment of Systemic Sclerosis A Comprehensive Review of Recent Developments

Moreau,

Kulak,

Sokołowska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a multifaceted autoimmune disorder characterized by widespread organ involvement, impacting the skin, lungs, gastrointestinal tract, and blood vessels. Patients often confront a reduced lifespan, primarily attributed to pulmonary complications. Current therapeutic strategies concentrate on organ-specific interventions to mitigate inflammation and alleviate symptoms. Immunosuppressive drugs, vasodilators, and anti-fibrotic agents are commonly employed, but ongoing research explores novel drugs and therapeutic approaches. Autologous stem cell transplantation is considered in rapidly progressing interstitial lung disease, although potential complications must be carefully weighed. Recent studies delve into the intricate pathogenesis of SSc, revealing abnormalities in metabolic pathways and protein regulation. The disease manifests with diverse symptoms affecting various organs, with vascular involvement significantly contributing to morbidity, especially pulmonary arterial hypertension. Complications, including heightened susceptibility to infections, are exacerbated by the disease and its treatments. Ongoing research investigates potential treatments such as GPR68 antagonists, soluble guanylate cyclase activators, and melanocortin 1 receptor agonists, displaying promising results in improving pulmonary function. Multiple clinical trials for various drugs are currently underway. In conclusion, addressing the complexities of systemic sclerosis requires a multidisciplinary approach. Understanding its intricate pathogenesis and developing targeted therapies are pivotal for enhancing patient outcomes and extending survival.

show abstract

Section: Symptomsmentioning

confidence: 99%